ANTX
NASDAQAN2 Therapeutics Inc.
Website
News25/Ratings12
Price$4.30+3.10 (+259.83%)
2026-01-202026-04-23
News · 26 weeks68-54%
2025-10-262026-04-19
Mix5290d
- Insider30(58%)
- SEC Filings14(27%)
- Other8(15%)
Latest news
25 items- SECSEC Form DEF 14A filed by AN2 Therapeutics Inc.DEF 14A - AN2 Therapeutics, Inc. (0001880438) (Filer)
- SECSEC Form DEFA14A filed by AN2 Therapeutics Inc.DEFA14A - AN2 Therapeutics, Inc. (0001880438) (Filer)
- SECSEC Form EFFECT filed by AN2 Therapeutics Inc.EFFECT - AN2 Therapeutics, Inc. (0001880438) (Filer)
- SECSEC Form 424B3 filed by AN2 Therapeutics Inc.424B3 - AN2 Therapeutics, Inc. (0001880438) (Filer)
- SECSEC Form 424B5 filed by AN2 Therapeutics Inc.424B5 - AN2 Therapeutics, Inc. (0001880438) (Filer)
- INSIDERSEC Form 4 filed by Aziz Kabeer4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDERSEC Form 4 filed by Marks Gilbert Lynn4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDERSEC Form 4 filed by Martin Patricia A.4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SECSEC Form S-3 filed by AN2 Therapeutics Inc.S-3 - AN2 Therapeutics, Inc. (0001880438) (Filer)
- SECSEC Form 8-K filed by AN2 Therapeutics Inc.8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)
- PRAN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung DiseaseAN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the initiation of a Phase 2 investigator-initiated clinical trial evaluating the safety, efficacy, and pharmacokinetics of epetraborole, an orally administered inhibitor of leucyl-tRNA synthetase (LeuRS), for the treatment of pulmonary disease caused by Mycobacterium abscessus (M. abscessus). The 84-patient, multicenter, randomized, double-blind study is being led by Dr. Kevin Winthrop at Oregon Health & Science University (OHSU), in collaboration with other investigators across an estimated 10-15 sites in th
- SECSEC Form D filed by AN2 Therapeutics Inc.D - AN2 Therapeutics, Inc. (0001880438) (Filer)
- INSIDERSEC Form 4 filed by Day Lucy4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDERSEC Form 4 filed by Chanda Sanjay4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDERSEC Form 4 filed by Marks Gilbert Lynn4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDERSEC Form 4 filed by Aziz Kabeer4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDERSEC Form 4 filed by Martin Patricia A.4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDERSEC Form 4 filed by Fitzpatrick Margaret M4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDERSEC Form 4 filed by Wong Stephanie4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDERSEC Form 4 filed by Zakrzewski Joseph S4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDERSEC Form 4 filed by Eizen Joshua M4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDERSEC Form 4 filed by Spigelman Melvin K4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDERSEC Form 4 filed by Readnour Robin Shane4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDERSEC Form 4 filed by Easom Eric4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SECSEC Form 8-K filed by AN2 Therapeutics Inc.8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)